Table 1.

Competition between SIV mutants^a

SIVs in competition	Ratio of inoc. titersb	Exp. no.	Dominant aa sequencesc
			day 6		day 18
	4:1	#1	205D		205D
		#2	205D		205D
SIVmac239 & SIVmac239Gag205E	1:1	#1	205D		205D
		#2	205D		205D
	1:4	#1	205D		205D
		#2	205D		205D
	4:1	#1	205D	312A	205D	312A
		#2	205D	312A	205D	312A
SIVmac239 & SIVmac239Gag205E312P	1:1	#1	205D	312A	205D	312A
		#2	205D	312A	205D	312A
	1:4	#1	205D	312A	205D	312A
		#2	205D	312A	205D	312A
	4:1	#1	205D	340V	205D	340V
		#2	205D	340V	205D	340V
SIVmac239 & SIVmac239Gag205E340M	1:1	#1	205D/E	340V/M	205E	340M
		#2	205D/E	340V/M	205E	340M
	1:4	#1	205E	340M	205E	340M
		#2	205E	340M	205E	340M
	4:1	#1	205E	312P	205E	312P
		#2	205E	312P	205E	312P
SIVmac239Gag205E & SIVmac239Gag205E312P	1:1	#1	205E	312P	205E	312P
		#2	205E	312P	205E	312P
	1:4	#1	205E	312P	205E	312P
		#2	205E	312P	205E	312P
	4:1	#1	205E	340M	205E	340M
		#2	205E	340M	205E	340M
SIVmac239Gag205E & SIVmac239Gag205E340M	1:1	#1	205E	340M	205E	340M
		#2	205E	340M	205E	340M
	1:4	#1	205E	340M	205E	340M
		#2	205E	340M	205E	340M

^aHSC-F cells were coinfected with two kinds of SIVs indicated. Viral gag fragments were amplified by RT-PCR from viral RNAs from the culture supernatants on days 6 and 18 postinfection and then sequenced. Results from two sets of experiments (Exp. #1 and #2) are shown.

^bThe ratio of the dose (RT activity) of the virus indicated at the top to that at the bottom at coinfection.

^cDominant amino acid sequences at the positions where mutations were included in the inoculums are shown. 205D/E, D and E were detected equally at the 205th aa in Gag; 340 V/M, V and M were detected equally at the 340th aa in Gag.